Comparative Clinical and Metabolic Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 1 Diabetes: A Retrospective Cohort Study from Saudi Arabia

Both GLP-1 RAs and SGLT2 inhibitors effectively improve glycemic control and cardiovascular risk markers in T1D, with distinct advantages in weight loss and renal function, respectively. These findings highlight the value of personalized adjunct therapy choices to optimize patient outcomes. Larger prospective studies are needed to confirm long-term benefits and safety.